Zobrazeno 1 - 6
of 6
pro vyhledávání: '"Nina Deppisch"'
Publikováno v:
Molecular Medicine, Vol 19, Iss 1, Pp 54-61 (2013)
Abstract Trifunctional bispecific antibodies (trAbs) used in tumor immunotherapy have the unique ability to recruit T cells toward antigens on the tumor cell surface and, moreover, to activate accessory cells through their immunoglobulin Fc region in
Externí odkaz:
https://doaj.org/article/08ec4f4b1668430db55894883c0eab70
Autor:
Ralph Mocikat, Horst Lindhofer, Raymund Buhmann, Frauke Neff, Nina Eissler, Peter Ruf, Nina Deppisch
Trifunctional bispecific antibodies (trAb) are novel anticancer drugs that recruit and activate different types of immune effector cells at the targeted tumor. Thus, tumor cells are effectively eliminated and a long-lasting tumor-specific T-cell memo
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::251f0d06a62bf4124467a82046de7771
https://doi.org/10.1158/1535-7163.c.6538330.v1
https://doi.org/10.1158/1535-7163.c.6538330.v1
Autor:
Ralph Mocikat, Horst Lindhofer, Raymund Buhmann, Frauke Neff, Nina Eissler, Peter Ruf, Nina Deppisch
Supplementary Figures S1-S4. Supplementary Figure S1. Development of anti-antibodies following Surek treatment; Supplementary Figure S2. Activation and proliferation of T cells after treatment with trAb Surek alone; Supplementary Figure S3. Weight lo
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::023d321dc26b367a9ecbc369a4022d5d
https://doi.org/10.1158/1535-7163.22506214
https://doi.org/10.1158/1535-7163.22506214
Autor:
Nina Eissler, Ralph Mocikat, Raymund Buhmann, Horst Lindhofer, Peter Ruf, Frauke Neff, Nina Deppisch
Publikováno v:
Molecular Cancer Therapeutics. 14:1877-1883
Trifunctional bispecific antibodies (trAb) are novel anticancer drugs that recruit and activate different types of immune effector cells at the targeted tumor. Thus, tumor cells are effectively eliminated and a long-lasting tumor-specific T-cell memo
Publikováno v:
Mol. Med. 19, 54-61 (2013)
Trifunctional bispecific antibodies (trAbs) used in tumor immunotherapy have the unique ability to recruit T cells toward antigens on the tumor cell surface and, moreover, to activate accessory cells through their immunoglobulin Fc region interacting
Publikováno v:
Oncotarget
Oncotarget 8, 4520-4529 (2017)
Oncotarget 8, 4520-4529 (2017)
// Nina Deppisch 1 , Peter Ruf 2 , Nina Eisler 1 , Horst Lindhofer 2 , Ralph Mocikat 1, 3 1 Institut fur Molekulare Immunologie, Helmholtz-Zentrum Munchen, Germany 2 Trion Research GmbH, Martinsried, Germany 3 AG Translationale Molekulare Immunologie